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• BPD diagnosis tends towards remission over time. 
(Biskin, 2015; Zanarini, 2012)
• Main prospective studies (MSAD, CLPS) carried out 
in US population. Recent studies in other countries 
provided data for generalization of findings.
• Long-term follow-up data in clinical studies: 
Treatment response vs. natural remission (Paris, 2002)
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QUESTIONS
• What is the long-term course of BPD 
diagnostic remission in adulthood?
• Is the initial treatment related to long-term 
BPD remission rates? 
Overall hours of formal therapy
=  Nº of therapy sessions per month 
* hours per session * months in treatment
• Medline, PsycINFO and Scopus 
• Between 1990 and 2015. 
Inclusion criteria: 
1.   Adult BPD sample, diagnosed by semi-
structured interview
2.   BPD diagnosis at baseline and at least 
at one follow-up assessment
3.   5 years or more of follow-up
SEARCH STRATEGY
& INCLUSION CRITERIA
Records identified through database 
searching
(n = 1408)
Additional records identified through 
other sources
(n =  37)




No prospective studies (n = 306)
No adult sample (n= 39)
No BPD sample (n= 100)
Full-text articles assessed for 
eligibility
(n = 156)
Full-text articles excluded (n = 146)
No diagnostic interview (n=4)
No repeated outcome measure         
(BPD diagnosis)  (n= 50)
< 5 years of follow-up (n= 92)
Studies included in qualitative 
synthesis
(n = 10)












Cumulative remission rate: % n-period of remission over time of
follow-up, by cumulative survival analyses  (CLPS/MSAD, except at 6y)
Remission rate: % remission at an specific time point
– BPD diagnostic criteria:  DSM-III /DSM-III-R/ DSM-IV
– Semistructured interviews:  DIB / SCID / IPDE
No publication bias
Egger’s test:


















Australia 6y 63 Specialized 
Therapy
30 29.4 63.3 96
MBT Trial
Bateman (2008)
UK 8y 93 Specialized 
Therapy
22 30.3 68 612
TAU 19 33.3 47 --
Boscot Trial (CBT-PD)
Davidson (2010)
UK 6y 72 Specialized 
Therapy 
43 32.4 83.3 192
TAU 33 31.4 84.6 --
Ullevål Trial (CP vs OIT)
Antonsen (2015)




McMaster University Study 
Links (1999)





US 6y 91 No exp
treatment
264 26.9 80.3
Vaanta Primary Care 
Depression Study (PD-VDS)
Riihimäki (2014)
Finland 5y 83 No exp
treatment
29 32 86
Barcelona Study Spain 10y 64 No exp
treatment
41 26.9 92.7
Germany Study Germany 14.4y 35 No exp
treatment
58 29.2 100
































Study name Subgroup within study Statistics for each study Event rate and 95%  CI
Event Lower Upper 
rate limit limit p-Value
Conversational Model Therapy Trial Specialized Therapy 0,40 0,24 0,58 0,28
Mentalization-based Trial Specialized Therapy 0,86 0,65 0,96 0,00
Mentalization-based Trial TAU 0,11 0,03 0,34 0,00
Boscot Trial Specialized Therapy 0,56 0,41 0,70 0,45
Boscot Trial TAU 0,52 0,35 0,68 0,86
Ullevål Trial Specialized Therapy 0,89 0,66 0,97 0,00
Ullevål Trial TAU 0,93 0,65 0,99 0,01
McMaster University Study No exp treatment 0,53 0,40 0,65 0,69
MSAD Study No exp treatment 0,69 0,63 0,74 0,00
Vaanta Primary Care Depression Study (PD-VDS) No exp treatment 0,31 0,17 0,50 0,05
Barcelona Study No exp treatment 0,55 0,40 0,69 0,53
Germany Study No exp treatment 0,72 0,60 0,82 0,00
0,59 0,48 0,69 0,13
-1,00 -0,50 0,00 0,50 1,00
Favours A Favours B
Meta Analysis
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Meta Analysis
Meta Analysis
Mean Remission rate:  59%  (48% - 69%)
High heterogeneity: Q= 54.9, p < .001
I2 = 80%  (> 75%)
Long-term BPD remission
General moderators:   Age  &  Gender
Mixed effects regression (unrestricted maximum likelihood)
Mean age 
% Remission
Q = 5.36, p = .02
% Women
% Remission






















Q = 1.11, p = .29
General moderators:  Time of Follow-up
Differences between treatment groups:    Q = 0.76,  p = .69 
Treatment moderators:
Type of experimental Treatment
Treatment moderators: 
Formal Therapy
Differences between treatment groups:    Q = 2.7,  p = .10 
Treatment moderators: 





Q = 0.41  p = .52







Hours of formal therapy
CONCLUSIONS: NATURAL COURSE
 Over a half of patients with BPD diagnosis may
achieve remission in the long term.
 A diagnosis of BPD at a younger age is associated
with higher long-term remission rates
 Female gender might be related to better clinical
outcome
 Time of follow-up seems not related to remission
after 5 years or more of illness.
 Specialized therapies seem not to improve the long-
term clinical outcome, compared to treatment as usual
or the natural course of the disorder.
 Receiving any kind of formal therapy might be 
associated with higher percentages of remission in the 
long term.
 The intensity and length of formal therapy received
appears not to be crucial in reaching a better outcome




 Limited number of studies and small size of BPD
samples in the majority of studies reduce the
statistical power and might compromise the study of
moderators
 Further research focused on the long-term outcome
of treatment interventions is strongly recommended.
 Longitudinal studies in untreated samples may
contribute to describe the natural course of BPD.
